8MM Alzheimer's Disease Market Drug Forecast And Market Analysis 2025-2033 Eisai, Biogen, And Lilly To Lead, Novel Late-Stage Pipeline Drugs Will Be A Key Driver, Opportunities In Unmet Needs

(MENAFN- GlobeNewsWire - Nasdaq) Alzheimer's market growth opportunities lie in developing disease-modifying treatments and anti-Aβ monoclonal antibodies, driven by unmet needs in AD therapies. The US and China dominate sales, with future expansions anticipated, requiring strategic in-licensing, partnerships, and innovation to capture growing demand.

Dublin, Sept. 10, 2025 (GLOBE NEWSWIRE) -- The "Alzheimer's Disease: Eight-Market Drug Forecast and Market Analysis - Update" report has been added to ResearchAndMarkets's offering.
This report covers the 8 major markets and provides an Excel-based forecast model for the Alzheimer's Disease market through 2033.
The analyst estimates that the value of the Alzheimer's Disease (AD) market in the 8MM in 2023 was $2.4 billion.

This market is defined as sales of symptamatic and disease modifying (DMT) treatments including including approval of anti-Ab monoclonal antibodies (mAbs) across the 8MM (US, France, Germany, Italy, Spain, UK, Japan and China). The US and China markets make up the majority of total global sales, contributing $1.1 billion (44.7%) and $915.2 million (38.8%), respectively.

The smallest market is France, contributing only 1.1% to total global sales, due to the lower AD prevalent population in the country, as well as the lack of reimbursement of the current AD symptomatic therapies resulting in lower treatment rates in France. By the end of the forecast period in 2033, The analyst projects AD sales to rise to $17.0 billion in the 8MM, at a compound annual growth rate (CAGR) of 21.8%.
Scope

• Overview of Alzheimer's Disease, including epidemiology, symptoms, diagnosis, and disease management.
• Annualized Alzheimer's Disease therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2023 to 2033.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the migraine therapeutics market.
• Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for Alzheimer's disease treatment. The most promising candidates in late-stage development are profiled.
• Analysis of the current and future market competition in the global Alzheimer's Disease therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the 8MM Alzheimer's Disease therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 8MM Alzheimer's Disease therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Key Topics Covered:
1 Alzheimer's Disease: Executive Summary
1.1 Summary of changes
1.2 Executive summary
1.3 Alzheimer's market forecast to see double-digit sales growth out to 2033
1.4 Eisai, Biogen, and Lilly are forecast to lead the AD market in 2033
1.5 Opportunities to fulfil key unmet needs will remain
1.6 Novel late-stage pipeline drugs will be a key driver of growth
1.7 What Do Physicians Think?
2 Introduction
2.1 Catalyst
2.2 Related reports
2.3 Upcoming reports
3 Disease Overview
3.1 Etiology
3.1.1 Risk genes
3.1.2 Deterministic genes
3.1.3 Protective genes
3.1.4 Metabolic disruption
3.2 Pathophysiology
3.2.1 Structural changes in the brain
3.2.2 Degenerative process
3.2.3 A? plaques
3.2.4 Neurofibrillary tangles
3.2.5 Neurotransmitter deficiencies
3.2.6 Oxidative stress
3.3 Biomarkers / targets of interest
3.4 Disease staging systems
3.5 Symptoms and prognosis
4 Epidemiology
4.1 Disease Background
4.2 Risk Factors and Comorbidities
4.3 Global and Historical Trends
4.4 Forecast Methodology
4.4.1 Sources
4.4.2 Forecast Assumptions and Methods
4.4.3 Forecast assumptions and methods: total prevalent cases of AD by DSM-IV criteria
4.4.4 Forecast assumptions and methods: total prevalent cases of AD by severity
4.4.5 Forecast assumptions and methods: total prevalent cases of preclinical AD
4.4.6 Forecast assumptions and methods: total prevalent cases of MCI
4.5 Epidemiological Forecast for AD (2023-33)
4.5.1 Total prevalent cases of AD by DSM-IV criteria
4.5.2 Age-specific total prevalent cases of AD by DSM-IV criteria
4.5.3 Sex-specific total prevalent cases of AD by DSM-IV criteria
4.5.4 Total prevalent cases of AD by severity
4.5.5 Total prevalent cases of preclinical AD
4.5.6 Age-specific total prevalent cases of preclinical AD
4.5.7 Sex-specific total prevalent cases of preclinical AD
4.5.8 Total prevalent cases of MCI
4.5.9 Age-specific total prevalent cases of MCI
4.5.10 Sex-specific total prevalent cases of MCI
4.6 Discussion
4.6.1 Epidemiological forecast insight
4.6.2 COVID-19 impact
4.6.3 Limitations of the Analysis
4.6.4 Strengths of the Analysis
5 Disease Management
5.1 Diagnosis and treatment overview
5.2 KOL insights on disease management
6 Current Treatment Options
6.1 Overview
7 Unmet Needs and Opportunity Assessment
7.1 Overview
7.2 More efficacious DMTs
7.3 Improved control of behavioral symptoms
7.4 Symptomatic drugs for cognition
7.5 Improving diagnosis earlier in the disease progression
7.6 Access to treatment
8 R&D Strategies
8.1 Overview
8.1.1 Targeting A?
8.1.2 Novel MOAs
8.1.3 Targeting agitation and psychosis
8.1.4 Targeting preclinical AD
8.1.5 Combination therapies
8.1.6 Non-pharmacological treatments
8.2 Clinical Trials Design
8.2.1 Inclusion/exclusion criteria
8.2.2 Endpoints
8.2.3 Use of biomarkers in trial design
9 Pipeline Assessment
9.1 Overview
9.2 Promising drugs in clinical development
10 Pipeline Valuation Analysis
10.1 Overview
10.2 Competitive Assessment
10.2.1 Potential DMTs
10.2.2 Therapies for agitation and psychosis associated with AD
11 Current and Future Players
11.1 Overview
11.2 Deal-Making Trends
12 Market Outlook
12.1 Global Markets
12.1.1 Forecast
12.1.2 Drivers and barriers - global issues
12.2 US
12.2.1 Forecast
12.2.2 Key Events
12.2.3 Drivers and Barriers
12.3 5EU
12.3.1 Forecast
12.3.2 Key Events
12.3.3 Drivers and Barriers
12.4 Japan
12.4.1 Forecast
12.4.2 Key events
12.4.3 Drivers and barriers
12.5 China
12.5.1 Forecast
12.5.2 Key events
12.5.3 Drivers and barriers
13 Appendix

Companies Featured

• Eli Lilly and Co
• Otsuka Pharmaceutical Co Ltd
• Novartis AG
• Biogen Inc
• Eisai Co Ltd
• Suven Life Sciences Ltd
• Towa Pharmaceutical Co Ltd
• AB Science SA
• H. Lundbeck AS
• Neurimmune Holding AG
• Annovis Bio Inc
• Teikoku Seiyaku Co Ltd
• AbbVie Inc
• BioVie Inc
• Alzheon Inc
• Axsome Therapeutics Inc
• TauRx Pharmaceuticals Ltd
• Anavex Life Sciences Corp
• Shanghai Green Valley Pharmaceutical Co Ltd
• Johnson & Johnson
• Corium LLC
• Bristol-Myers Squibb Co
• Ono Pharmaceutical Co Ltd
• Novo Nordisk AS
• Daiichi Sankyo Co Ltd
• AriBio Co Ltd
• Luye Pharma Group Ltd
• BioXcel Therapeutics Inc
• AlphaCognition Inc
• Biomed Industries Inc
• Cerecin Inc

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN10092025004107003653ID1110043811